重组人血小板生成素治疗急性髓系白血病化疗后血小板减少的临床疗效

Clinical Effect of Recombinant Human Thrombopoietin in Treatment of Thrombocytopenia of Acute Myeloid Leukemia after Chemotherapy

目的分析重组人血小板生成素(rhTPO)治疗急性髓系白血病(AML)化疗后血小板减少的临床疗效。方法选取2018年1月—2023年1月本院收治的10例AML化疗后血小板减少患者作为观察对象,按照是否予以rhTPO治疗,分为对照组(未行rhTPO治疗)和观察组(行rhTPO治疗),每组5例,比较应用效果。结果观察组血小板改善时间短于对照组(P<0.05);观察组血小板输注次数、单采血小板数量少于对照组(P<0.05);观察组无恶性不良事件发生。结论采用rhTPO治疗AML化疗后血小板减少患者,可促进血小板提升,减少血小板输注次数、单采血小板数量,且不良反应轻微,安全性高,可推广。

Objective To analyze clinical effect of recombinant human thrombopoietin(rhTPO)in treatment of thrombocytopenia of acute myeloid leukemia(AML)after chemotherapy.Methods The paper chose 10 AML patients with thrombocytopenia after chemotherapy in our hospital from January 2018 to January 2023 as observation subjects,and divided them into control group(with no rhTPO treatment)and observation group(with rhTPO treatment)according being treated with rhTPO or not,with 5 cases in each group.Application effect was compared between groups.Results Improvement time of platelets in observation group was shorter than control group(P<0.05).Number of platelet transfusions and single platelet counts in observation group were less than control group(P<0.05).There were no malignant adverse events in observation group.Conclusion rhTPO treatment can promote platelet improvement,reduce platelet transfusion frequency and platelet count of AML patients with chemotherapy-induced thrombocytopenia,with mild adverse reactions and high safety,which can be promoted.